PortalPublikationenOutcome after relapse of myelodysplastic syndrome and second...

Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation

Standard

Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation. / Schmid, Christoph; de Wreede, Liesbeth C; van Biezen, Anja; Finke, Jürgen; Ehninger, Gerhard; Ganser, Arnold; Volin, Liisa; Niederwieser, Dietger; Beelen, Dietrich; Alessandrino, Paolo; Kanz, Lothar; Schleuning, Michael; Passweg, Jakob; Veelken, Hendrik; Maertens, Johan; Cornelissen, Jan J; Blaise, Didier; Gramatzki, Martin; Milpied, Noel; Yakub-Agha, Ibrahim; Mufti, Ghulam; Rovira, Montserrat; Arnold, Renate; De Witte, Theo; Robin, Marie; Kröger, Nikolaus.

in: HAEMATOLOGICA, Jahrgang 103, Nr. 2, 02.2018, S. 237-245.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Schmid, C, de Wreede, LC, van Biezen, A, Finke, J, Ehninger, G, Ganser, A, Volin, L, Niederwieser, D, Beelen, D, Alessandrino, P, Kanz, L, Schleuning, M, Passweg, J, Veelken, H, Maertens, J, Cornelissen, JJ, Blaise, D, Gramatzki, M, Milpied, N, Yakub-Agha, I, Mufti, G, Rovira, M, Arnold, R, De Witte, T, Robin, M & Kröger, N 2018, 'Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation', HAEMATOLOGICA, Jg. 103, Nr. 2, S. 237-245. https://doi.org/10.3324/haematol.2017.168716

APA

Schmid, C., de Wreede, L. C., van Biezen, A., Finke, J., Ehninger, G., Ganser, A., Volin, L., Niederwieser, D., Beelen, D., Alessandrino, P., Kanz, L., Schleuning, M., Passweg, J., Veelken, H., Maertens, J., Cornelissen, J. J., Blaise, D., Gramatzki, M., Milpied, N., ... Kröger, N. (2018). Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation. HAEMATOLOGICA, 103(2), 237-245. https://doi.org/10.3324/haematol.2017.168716

Vancouver

Schmid C, de Wreede LC, van Biezen A, Finke J, Ehninger G, Ganser A et al. Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation. HAEMATOLOGICA. 2018 Feb;103(2):237-245. https://doi.org/10.3324/haematol.2017.168716

Bibtex

@article{70680fe4ea6a432cb791eeb1a7abc120,
title = "Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation",
abstract = "No standard exists for the treatment of myelodysplastic syndrome relapsing after allogeneic stem cell transplantation. We performed a retrospective registry analysis of outcomes and risk factors in 698 patients, treated with different strategies. The median overall survival from relapse was 4.7 months (95% confidence interval: 4.1-5.3) and the 2-year survival rate was 17.7% (95% confidence interval: 14.8-21.2%). Shorter remission after transplantation (P<0.001), advanced disease (P=0.001), older age (P=0.007), unrelated donor (P=0.008) and acute graft-versus-host disease before relapse (P<0.001) adversely influenced survival. At 6 months from relapse, patients had received no cellular treatment, (i.e. palliative chemotherapy or best supportive care, n=375), donor lymphocyte infusion (n=213), or a second transplant (n=110). Treatment groups were analyzed separately because of imbalanced characteristics and difficulties in retrospectively evaluating the reason for individual treatments. Of the patients who did not receive any cellular therapy, 109 were alive at 6 months after relapse, achieving a median overall survival from this landmark of 8.9 months (95% confidence interval: 5.1-12.6). Their 2-year survival rate was 29.7%. Recipients of donor lymphocytes achieved a median survival from first infusion of 6.0 months (95% confidence interval: 3.7-8.3) with a 2-year survival rate of 27.6%. Longer remission after first transplantation (P<0.001) and younger age (P=0.009) predicted better outcome. Among recipients of a second transplant, the median survival from second transplantation was 4.2 months (95% confidence interval: 2.5-5.9), and their 2-year survival rate was 17.0%. Longer remission after first transplantation (P<0.001), complete remission at second transplant (P=0.008), no prior chronic graft-versus-host disease (P<0.001) and change to a new donor (P=0.04) predicted better outcome. The data enabled identification of patients benefiting from donor lymphocyte infusion and second transplantation, and may serve as a baseline for prospective trials.",
keywords = "Journal Article, Myelodysplastic Syndromes/pathology, Recurrence, Reoperation, Europe, Humans, Middle Aged, Risk Factors, Male, Treatment Outcome, Leukemia, Myeloid, Acute/etiology, Young Adult, Allografts, Hematopoietic Stem Cell Transplantation/methods, Adolescent, Adult, Female, Registries, Aged, Retrospective Studies, Lymphocyte Transfusion",
author = "Christoph Schmid and {de Wreede}, {Liesbeth C} and {van Biezen}, Anja and J{\"u}rgen Finke and Gerhard Ehninger and Arnold Ganser and Liisa Volin and Dietger Niederwieser and Dietrich Beelen and Paolo Alessandrino and Lothar Kanz and Michael Schleuning and Jakob Passweg and Hendrik Veelken and Johan Maertens and Cornelissen, {Jan J} and Didier Blaise and Martin Gramatzki and Noel Milpied and Ibrahim Yakub-Agha and Ghulam Mufti and Montserrat Rovira and Renate Arnold and {De Witte}, Theo and Marie Robin and Nikolaus Kr{\"o}ger",
note = "Copyright{\textcopyright} 2018 Ferrata Storti Foundation.",
year = "2018",
month = feb,
doi = "10.3324/haematol.2017.168716",
language = "English",
volume = "103",
pages = "237--245",
journal = "HAEMATOLOGICA",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "2",

}

RIS

TY - JOUR

T1 - Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation

AU - Schmid, Christoph

AU - de Wreede, Liesbeth C

AU - van Biezen, Anja

AU - Finke, Jürgen

AU - Ehninger, Gerhard

AU - Ganser, Arnold

AU - Volin, Liisa

AU - Niederwieser, Dietger

AU - Beelen, Dietrich

AU - Alessandrino, Paolo

AU - Kanz, Lothar

AU - Schleuning, Michael

AU - Passweg, Jakob

AU - Veelken, Hendrik

AU - Maertens, Johan

AU - Cornelissen, Jan J

AU - Blaise, Didier

AU - Gramatzki, Martin

AU - Milpied, Noel

AU - Yakub-Agha, Ibrahim

AU - Mufti, Ghulam

AU - Rovira, Montserrat

AU - Arnold, Renate

AU - De Witte, Theo

AU - Robin, Marie

AU - Kröger, Nikolaus

N1 - Copyright© 2018 Ferrata Storti Foundation.

PY - 2018/2

Y1 - 2018/2

N2 - No standard exists for the treatment of myelodysplastic syndrome relapsing after allogeneic stem cell transplantation. We performed a retrospective registry analysis of outcomes and risk factors in 698 patients, treated with different strategies. The median overall survival from relapse was 4.7 months (95% confidence interval: 4.1-5.3) and the 2-year survival rate was 17.7% (95% confidence interval: 14.8-21.2%). Shorter remission after transplantation (P<0.001), advanced disease (P=0.001), older age (P=0.007), unrelated donor (P=0.008) and acute graft-versus-host disease before relapse (P<0.001) adversely influenced survival. At 6 months from relapse, patients had received no cellular treatment, (i.e. palliative chemotherapy or best supportive care, n=375), donor lymphocyte infusion (n=213), or a second transplant (n=110). Treatment groups were analyzed separately because of imbalanced characteristics and difficulties in retrospectively evaluating the reason for individual treatments. Of the patients who did not receive any cellular therapy, 109 were alive at 6 months after relapse, achieving a median overall survival from this landmark of 8.9 months (95% confidence interval: 5.1-12.6). Their 2-year survival rate was 29.7%. Recipients of donor lymphocytes achieved a median survival from first infusion of 6.0 months (95% confidence interval: 3.7-8.3) with a 2-year survival rate of 27.6%. Longer remission after first transplantation (P<0.001) and younger age (P=0.009) predicted better outcome. Among recipients of a second transplant, the median survival from second transplantation was 4.2 months (95% confidence interval: 2.5-5.9), and their 2-year survival rate was 17.0%. Longer remission after first transplantation (P<0.001), complete remission at second transplant (P=0.008), no prior chronic graft-versus-host disease (P<0.001) and change to a new donor (P=0.04) predicted better outcome. The data enabled identification of patients benefiting from donor lymphocyte infusion and second transplantation, and may serve as a baseline for prospective trials.

AB - No standard exists for the treatment of myelodysplastic syndrome relapsing after allogeneic stem cell transplantation. We performed a retrospective registry analysis of outcomes and risk factors in 698 patients, treated with different strategies. The median overall survival from relapse was 4.7 months (95% confidence interval: 4.1-5.3) and the 2-year survival rate was 17.7% (95% confidence interval: 14.8-21.2%). Shorter remission after transplantation (P<0.001), advanced disease (P=0.001), older age (P=0.007), unrelated donor (P=0.008) and acute graft-versus-host disease before relapse (P<0.001) adversely influenced survival. At 6 months from relapse, patients had received no cellular treatment, (i.e. palliative chemotherapy or best supportive care, n=375), donor lymphocyte infusion (n=213), or a second transplant (n=110). Treatment groups were analyzed separately because of imbalanced characteristics and difficulties in retrospectively evaluating the reason for individual treatments. Of the patients who did not receive any cellular therapy, 109 were alive at 6 months after relapse, achieving a median overall survival from this landmark of 8.9 months (95% confidence interval: 5.1-12.6). Their 2-year survival rate was 29.7%. Recipients of donor lymphocytes achieved a median survival from first infusion of 6.0 months (95% confidence interval: 3.7-8.3) with a 2-year survival rate of 27.6%. Longer remission after first transplantation (P<0.001) and younger age (P=0.009) predicted better outcome. Among recipients of a second transplant, the median survival from second transplantation was 4.2 months (95% confidence interval: 2.5-5.9), and their 2-year survival rate was 17.0%. Longer remission after first transplantation (P<0.001), complete remission at second transplant (P=0.008), no prior chronic graft-versus-host disease (P<0.001) and change to a new donor (P=0.04) predicted better outcome. The data enabled identification of patients benefiting from donor lymphocyte infusion and second transplantation, and may serve as a baseline for prospective trials.

KW - Journal Article

KW - Myelodysplastic Syndromes/pathology

KW - Recurrence

KW - Reoperation

KW - Europe

KW - Humans

KW - Middle Aged

KW - Risk Factors

KW - Male

KW - Treatment Outcome

KW - Leukemia, Myeloid, Acute/etiology

KW - Young Adult

KW - Allografts

KW - Hematopoietic Stem Cell Transplantation/methods

KW - Adolescent

KW - Adult

KW - Female

KW - Registries

KW - Aged

KW - Retrospective Studies

KW - Lymphocyte Transfusion

U2 - 10.3324/haematol.2017.168716

DO - 10.3324/haematol.2017.168716

M3 - SCORING: Journal article

C2 - 29101205

VL - 103

SP - 237

EP - 245

JO - HAEMATOLOGICA

JF - HAEMATOLOGICA

SN - 0390-6078

IS - 2

ER -